Cardiol Therapeutics Inc.
HealthcareNASDAQ:CRDL · NASDAQ Capital Market
-$0.04 today
Vol 0.24M · Avg 0.69M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$36.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.39, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 -100.0% | $62.3K | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 | $0 -100.0% | $187.4K +15.5% | $162.2K -6.9% | $174.3K | $725.6M | $804.0M | $882.4M |
| Gross Profit | $0 | $0 +100.0% | -$187.4K -15.5% | -$162.2K -44.8% | -$112.0K | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | -179.9% | 9.8% | 28.9% | 38.3% |
| Research & Development | $14.0M +0.0% | $14.0M +30.6% | $10.7M -23.3% | $14.0M +62.8% | $8.6M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $20.2M -23.1% | $26.3M +127.3% | $11.6M -29.3% | $16.3M -25.2% | $21.9M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $34.3M -14.8% | $40.3M +80.7% | $22.3M -26.5% | $30.3M -0.4% | $30.5M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $102.0K -37.1% | $162.1K -13.5% | $187.4K +15.5% | $162.2K -6.9% | $174.3K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$33.7M +7.7% | -$36.5M -73.6% | -$21.0M +7.2% | -$22.7M +8.8% | -$24.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | -39891.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$34.3M +14.8% | -$40.3M -79.2% | -$22.5M +26.3% | -$30.5M +0.2% | -$30.6M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | -49092.4% | 16.6% | 24.1% | 22.0% |
| Interest Income | $726.4K -39.1% | $1.2M -41.5% | $2.0M +64.7% | $1.2M +1067.6% | $106.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $497.4K -86.2% | $3.6M +187.9% | $1.3M -83.7% | $7.7M +38.2% | $5.6M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$33.8M +7.8% | -$36.7M -72.8% | -$21.2M +7.0% | -$22.8M +8.8% | -$25.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | -40170.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$33.8M +7.8% | -$36.7M -72.8% | -$21.2M +7.0% | -$22.8M +8.8% | -$25.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | -40170.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 +23.5% | -$1 -15.9% | -$0 +10.2% | -$0 +32.9% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 +23.5% | -$1 -15.9% | -$0 +10.2% | -$0 +32.9% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $87.0M +21.5% | $71.6M +11.0% | $64.5M +3.1% | $62.5M +44.6% | $43.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $87.0M +21.5% | $71.6M +11.0% | $64.5M +3.1% | $62.5M +44.6% | $43.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Assertio Holdings, Inc.
NASDAQ:ASRT
$151.73M
Connect Biopharma Holdings Limited
NASDAQ:CNTB
$133.48M
InflaRx N.V.
NASDAQ:IFRX
$115.57M
Hyperfine, Inc.
NASDAQ:HYPR
$114.53M
Microbot Medical Inc.
NASDAQ:MBOT
$81.12M
Kalaris Therapeutics Inc
NASDAQ:KLRS
$80.98M
Vivani Medical, Inc.
NASDAQ:VANI
$64.99M
ImageneBio Inc
NASDAQ:IMA
$63.39M
InterCure Ltd.
INCR
$47.79M
InspireMD, Inc.
NSPR
$34.19M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does CRDL generate?
Cardiol Therapeutics Inc. (CRDL) reported $0.00 of revenue in fiscal 2025.
Is CRDL profitable?
Cardiol Therapeutics Inc. (CRDL) reported -$33,818,874.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.